SecSonar.com

NewAmsterdam Pharma Company N.V. (NAMS)

NewAmsterdam Pharma Company N.V. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

NewAmsterdam Pharma Company N.V. (NAMS) is a Biotechnology company based in NL with a market capitalization of $3.9B. Revenue declined 50.6% year-over-year and free cash flow was negative at -$148M. This page tracks NAMS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

NL · 68 employees · IPO Feb 9, 2021

Valuation

Valuation & price

$35.44 · as of May 17, 2026 · -14.5% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

5.77

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$41.30$30.38$19.46Jul 25Dec 25Jul 26Jul 7, 25$19.46Jul 9, 25$21.64Jul 11, 25$21.54Jul 15, 25$21.02Jul 17, 25$21.98Jul 21, 25$22.56Jul 23, 25$23.98Jul 25, 25$23.60Jul 29, 25$22.78Jul 31, 25$21.81Aug 4, 25$21.66Aug 6, 25$23.62Aug 11, 25$24.37Aug 13, 25$25.76Aug 15, 25$25.07Aug 19, 25$24.45Aug 21, 25$24.44Aug 25, 25$24.70Aug 27, 25$24.47Aug 29, 25$24.05Sep 3, 25$24.88Sep 5, 25$27.00Sep 9, 25$26.60Sep 11, 25$26.60Sep 16, 25$24.52Sep 18, 25$26.73Sep 22, 25$27.05Sep 24, 25$26.76Sep 26, 25$28.50Sep 30, 25$28.44Oct 2, 25$30.70Oct 6, 25$32.48Oct 8, 25$32.86Oct 10, 25$37.05Oct 14, 25$37.86Oct 16, 25$36.47Oct 21, 25$36.48Oct 23, 25$36.28Oct 27, 25$36.04Oct 29, 25$35.84Oct 31, 25$37.95Nov 4, 25$36.53Nov 6, 25$37.05Nov 10, 25$38.97Nov 12, 25$38.31Nov 14, 25$38.35Nov 18, 25$38.91Nov 20, 25$37.71Nov 25, 25$40.44Nov 28, 25$41.30Dec 2, 25$38.33Dec 4, 25$35.85Dec 8, 25$35.75Dec 10, 25$35.61Dec 12, 25$37.25Dec 16, 25$34.22Dec 18, 25$33.90Dec 22, 25$36.49Dec 24, 25$35.65Dec 29, 25$35.02Jan 2, 26$35.20Jan 6, 26$34.02Jan 8, 26$35.80Jan 12, 26$32.69Jan 14, 26$31.92Jan 16, 26$31.65Jan 21, 26$33.94Jan 23, 26$33.32Jan 27, 26$32.63Jan 29, 26$31.44Feb 2, 26$31.57Feb 4, 26$32.98Feb 9, 26$35.00Feb 11, 26$34.24Feb 13, 26$34.63Feb 18, 26$35.76Feb 20, 26$35.58Feb 24, 26$36.01Feb 26, 26$34.28Mar 2, 26$32.83Mar 4, 26$31.18Mar 6, 26$29.86Mar 10, 26$31.27Mar 12, 26$29.82Mar 17, 26$30.60Mar 19, 26$30.46Mar 23, 26$30.01Mar 25, 26$31.01Mar 27, 26$29.98Mar 31, 26$32.01Apr 2, 26$32.99Apr 7, 26$33.91Apr 9, 26$35.07Apr 13, 26$36.25Apr 15, 26$34.01Apr 17, 26$34.68Apr 22, 26$31.94Apr 24, 26$29.72Apr 28, 26$28.72Apr 30, 26$28.56May 4, 26$29.86May 6, 26$30.99May 8, 26$38.73May 12, 26$38.89May 14, 26$36.88May 18, 26$34.14May 20, 26$35.75May 22, 26$35.44May 28, 26$35.42Jun 1, 26$31.79Jun 3, 26$32.11Jun 5, 26$31.52Jun 9, 26$30.38Jun 11, 26$30.26Jun 15, 26$30.60Jun 17, 26$30.15Jun 22, 26$30.82Jun 24, 26$32.63Jun 26, 26$33.24Jul 2, 26$34.83
$19.4652-week range$41.45
Loading valuation history…

Fundamentals

Key fundamentals

$3.9B

Market cap

-50.6%

Revenue growth (YoY)

99.7%

Gross margin

-$148M

Free cash flow (USD)

-$636M

Net debt

Net cash position

21.2%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2020 → 2025

FY 2020$0.00FY 2021$0.00FY 2022$102.7MFY 2023$14.1MFY 2024$45.6MFY 2025$22.5M
$0$22.5M

Free cash flow by year

2020 → 2025

FY 2020$-7.4MFY 2021$-29.5MFY 2022$10.4MFY 2023$-141.2MFY 2024$-159.2MFY 2025$-148.0M
-$7.4M-$148M

Gross margin by year

2022 → 2025

FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 202599.7%
100.0%99.7%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

2

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $1.2MKooij Louise Frederika · Chief Accounting Officer · $1.2MJun 24, 2026Filing
  • 8-K eventEmployee Stock Purchase PlanJun 3, 2026Filing
  • Insider sellInsider Sell $2.3MKooij Louise Frederika · Chief Accounting Officer · $2.3MMay 27, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventCorporate Update and Financial ResultsMay 7, 2026Filing
  • 8-K eventChief Accounting Officer DepartureApr 24, 2026Filing

Questions

Frequently asked questions

What is NewAmsterdam Pharma Company N.V.'s market cap?

NewAmsterdam Pharma Company N.V. (NAMS) has a market capitalization of $3.9B.

What is NAMS's P/E ratio?

A meaningful P/E ratio is not available for NAMS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is NAMS's price-to-book (P/B) ratio?

NAMS trades at 5.77 times book value per share.

Are insiders buying NAMS stock?

SEC Form 4 filings show no open-market insider buys at NewAmsterdam Pharma Company N.V. in the last 90 days (2 sells).

Same arena

Related companies in Biotechnology

CPRX

Catalyst Pharmaceuticals, Inc.

$3.8B

DNTH

Dianthus Therapeutics, Inc.

$3.8B

VCYT

Veracyte, Inc.

$3.8B

CRNX

Crinetics Pharmaceuticals, Inc.

$3.7B

ACAD

ACADIA Pharmaceuticals Inc.

$3.7B

KNSA

Kiniksa Pharmaceuticals, Ltd.

$3.7B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.